“We continue to make significant scientific progress that further validates InMed’s proprietary bioinformatics analysis tool as a cost-effective way to identify drug-disease targets and expedite their validation in preclinical models,” Dr. Ado Muhammed, InMed’s chief medical officer, also said in the press release. “In addition to our primary drug development programs in Epidermolysis Bullosa ad Glaucoma, we are pleased to continue to expand the role of cannabinoids in other disease areas.”
Cannabinoids have been used to treat other diseases, such as cancer. According to the American Cancer Society, two drugs based on marijuana compounds are approved for medical use in the U.S.
One of the cannabinoids, Dronabinol, is used to treat nausea and vomiting as a result of chemotherapy or poor appetite in AIDS patients. The second drug, Nabilone, is a synthetic cannabinoid with properties like THC, the active ingredient in marijuana. It also treats nausea and vomiting from chemotherapy.
Researchers are exploring the possibilities of cannabinoids in treating other conditions. This research could lead to new waves in medical marijuana and how it can be used for medical therapies.
